Gilead Sciences Acquires Arcellx to Boost Anito-cel’s Long-Term Potential
Gilead Sciences, Inc. has announced its acquisition of Arcellx for approximately $7.8 billion. This deal, which includes a cash payment of $115 per share and a $5 contingent value right, aims to enhance the potential of Anito-cel, a promising treatment for multiple myeloma.
Details of the Acquisition
The acquisition aligns with Gilead’s commitment to advancing solutions for patients with cancer. Through this agreement, Gilead will gain full control of Anito-cel, thereby expediting its development and commercialization. This move eliminates profit-sharing, milestones, and royalties originally involved in their partnership.
Background on Anito-cel
Anito-cel is an investigational CAR T-cell therapy designed specifically for treating relapsed or refractory multiple myeloma. Its efficacy and safety have been highlighted in recent clinical studies, making it a candidate for the Biologics License Application (BLA) currently under review.
Regulatory Milestones
- The FDA has accepted the BLA for Anito-cel.
- Anticipated Prescription Drug User Fee Act (PDUFA) date: December 23, 2026.
- Results supporting the BLA stem from the Phase 1 and pivotal Phase 2 iMMagine1 studies.
Gilead’s Strategic Vision
According to Daniel O’Day, Gilead’s Chairman and CEO, the acquisition reflects a belief in Anito-cel’s significant potential to become a foundational therapy for multiple myeloma. He emphasized the intent to expedite its launch and broaden access for patients.
Arcellx’s Innovative Technology
Arcellx’s technology platform, which includes D-Domain CAR technology, offers potential for next-generation therapies. These innovations seek to improve binding affinity and specificity, furthering advancements in CAR T-cell and bispecific therapies.
Transaction Terms and Timeline
The transaction is expected to finalize in the second quarter of 2026, contingent upon customary closing conditions and regulatory approvals. Gilead currently owns about 11.5% of Arcellx’s outstanding shares. The offer represents a 68% premium over Arcellx’s recent average stock price.
Future Outlook
Following FDA approval of Anito-cel, Gilead anticipates the acquisition will positively impact earnings per share beginning in 2028. The combined efforts of both companies aim to enhance patient care in oncology.
Gilead and Arcellx both recognize the innovative spirit and dedication their respective teams have shown throughout their journey. With this acquisition, they aspire to significantly elevate treatment options for patients facing multiple myeloma and other severe conditions.
